OUR STRATEGY

Download the pdf and discover our projects

Therapy
Cancer Biomarkers

THE PRODUCT

THE MARKET

Western Europe and USA

  • Europa occidentale, USA, Cina e Giappone
  • Lung, colon, ovary cancers new cases/ year: 700.000
  • Tumors expressing Trop-2: 500.000
  • Health services reimbursements: 30.000 €/ patient
  • Target total sales: 10 billion €/ year

Benchmark di mercato: Herceptin 7 miliardi € / anno

COMPETITORS

Immunomedics generated the humanized RS7 antibody conjugated to SN38 (Sacituzumab Govitecan, IMMU-132). This ADC, however, is based on outdated technologies (reduction of disulfide bridges). Similar technologies have been recently implemented by Daiichi Sankyo with the anti-Trop-2 ADC DS-1062, currently in lung cancer experimentation, obtaining corresponding results. Innovative conjugation technologies and the use of toxins of very high power can allow the ADC anti-Trop-2 Hu2g10 to become "best in class".

KEY RESOURCES

  • Leadership in the field of Trop-2 research
  • Unique know-how on the molecule
  • Proprietary anti-Trop-2 antibodies
  • Major collaborators network
  • Two granted strategic PCT (WO 2010/035304; WO 2010/089782); two pending PCT
  • main PCT:
    • antibodies & lines of hybridomas
    • production strategy → synergy of use
  • Efficacy in preclinical models
  • Regulatory activity planning